REVIEWING "APINACA", AN EMERGENT SYNTHETIC CANNABINOID RECEPTOR AGONIST

FN. Dinamarca ¹, L.Galindo ^{1,2,4}, M. Grifell ^{1,2}, M. Campillo ¹, V. Pérez ^{1,2,4}, M.Torrens ^{1,2,4}, M. Farré ^{2,3,4}

- 1. Institut de Neuropsiquiatria i Addiccions, Parc de salut mar, Barcelona, Spain.
- 2. Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.
- 3. Servei de Farmacología Clínica, Hospital Germans Trías i Pujol, Barcelona, Spain
- 4. Universidad Autónoma de Barcelona, Bellaterra, Spain

Introduction

Since 1990 there is an increase in the synthesis and in some cases the preclinical evaluation of new molecules that act on the cannabinoid synthesis, but no one have been marketed as a medicine. Recently, with the proliferation of New Psychoactive substances (NPS), an important number of synthetic cannabinoid appeared in the "legal high" market as Spice or other names. There is almost no research available and, despite its widespread use, the animal or human pharmacology of substances is unknown.


Objective

Reviewing literature for exposing the history and current state of knowledge of the AKB-48 molecule.

Material and methods

A review of the publications of the molecule is done by searching for keywords "AKB-48" "AKB48" "APINACA" "Synthetic cannabinoids" in Pubmed and Google scholar.

Results - Review



Conclusions

The European Early Warning System (EWS) informs specially an increase in the detection of new cannabinoids that are sold like "legal alternatives" of marijuana. APINACA is currently not under international control and, as we can see in this review, there is a lack of evidence and it has been described a potential harm. Further characterization of pharmacodynamics and pharmacokinetics of the compound is needed and also it's necessary to know the actual epidemiology of the use of this substance in order to determine the impact of its consumption and provide more information in understanding the cannabinoid system.

References

(1) Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y (2012). Identification of two new-type synthetic cannabinoids, N-(1-adamantyl)-1- pentyl-1H-indole-3-carboxamide (APICA) and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA), and detection of five synthetic cannabinoids, AM-1220, AM-2233, AM-1241, CB-13 (CRA-13), and AM-1248, as designer drugs in illegal products. Forensic Toxicol 30(2): 114-125
(2) Gandhi AS1, Zhu M, Pang S, Wohlfarth A, Scheidweiler KB, Liu HF, Huestis MA. First characterization of AKB-48 metabolism, a novel synthetic cannabinoid, using human hepatocytes and high-resolution mass spectrometry. AAPS J. 2013 Oct;15(4):1091-8. doi: 10.1208/s12248-013-9516-0. Epub 2013 Aug 3.

(3) Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y (2013). URB-754: a new class of designer drug and 12 synthetic cannabinoids detected in illegal products. Forensic Scilnt 227(1-3): 21-32.

(4) Expert Committee on Drug Dependence.APINACA, critical review report, Agenda ítem 4.9.Geneva, 16-20 June 2014 WHO.

(5) Hermanns-Clausen M, Kneisel S, Szabo B, Auwarter V (2013). Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 108(3): 534-544.

(6) Koller VJ, Ferk F, Al-Serori H, Mišík M, Nersesyan A, Auwärter V, Grummt T, Knasmüller S. Genotoxic properties of representatives of alkylindazoles and aminoalkyl-indoles which are consumed as synthetic cannabinoids. FoodChemToxicol. 2015 Mar 16;80:130-136. doi: 10.1016/j.fct.2015.03.004.

